Matthew S Stankowicz1, Jad Ibrahim2, Daniel L Brown2. 1. Matthew S. Stankowicz is a Pharm.D. student; Jad Ibrahim is a Pharm.D. student; and Daniel L. Brown, Pharm.D., is Professor of Pharmacy Practice and Director of Faculty Development, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL. matt_stankowicz@pba.edu. 2. Matthew S. Stankowicz is a Pharm.D. student; Jad Ibrahim is a Pharm.D. student; and Daniel L. Brown, Pharm.D., is Professor of Pharmacy Practice and Director of Faculty Development, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL.
Abstract
PURPOSE: The advantages and disadvantages of once-daily versus conventional dosing of aminoglycoside antibiotics are reviewed. SUMMARY: Although administration of multiple daily doses remains the standard method of aminoglycoside dosing, once-daily dosing may provide enhanced clinical efficacy and reduced toxicity in selected patient populations; demonstrated pharmacokinetic and pharmacodynamic advantages include enhanced postantibiotic effect and an increased likelihood of a high ratio of serum peak concentration to minimum inhibitory concentration. Published evidence identified in a MEDLINE search covering the period 1985-2014 indicates that once-daily high-dose aminoglycoside therapy generally provides clinical effectiveness equivalent or superior to that of multiple-daily dosing. The risk of nephrotoxicity appears to be comparable with once- and multiple-daily aminoglycoside dosing. Several nomograms have been developed to facilitate once-daily dosing; the Hartford nomogram (using a dose of 7 mg/kg) is the most extensively tested and generally considered the most reliable. However, although those nomograms are convenient to use and may reduce expenses, a daily dosing regimen determined by individualized pharmacokinetic monitoring is likely to be more effective for achieving specific serum concentrations and may be a preferable approach for some patients. Patients who are pregnant or have liver failure, severe renal insufficiency, serious illness, or nutritional deficiency are not appropriate candidates for once-daily dosing. CONCLUSION: Once-daily aminoglycoside dosing is an effective, well-established method to achieve therapeutic efficacy while limiting the risk of toxicity and simplifying the processes of dosing and monitoring.
PURPOSE: The advantages and disadvantages of once-daily versus conventional dosing of aminoglycoside antibiotics are reviewed. SUMMARY: Although administration of multiple daily doses remains the standard method of aminoglycoside dosing, once-daily dosing may provide enhanced clinical efficacy and reduced toxicity in selected patient populations; demonstrated pharmacokinetic and pharmacodynamic advantages include enhanced postantibiotic effect and an increased likelihood of a high ratio of serum peak concentration to minimum inhibitory concentration. Published evidence identified in a MEDLINE search covering the period 1985-2014 indicates that once-daily high-dose aminoglycoside therapy generally provides clinical effectiveness equivalent or superior to that of multiple-daily dosing. The risk of nephrotoxicity appears to be comparable with once- and multiple-daily aminoglycoside dosing. Several nomograms have been developed to facilitate once-daily dosing; the Hartford nomogram (using a dose of 7 mg/kg) is the most extensively tested and generally considered the most reliable. However, although those nomograms are convenient to use and may reduce expenses, a daily dosing regimen determined by individualized pharmacokinetic monitoring is likely to be more effective for achieving specific serum concentrations and may be a preferable approach for some patients. Patients who are pregnant or have liver failure, severe renal insufficiency, serious illness, or nutritional deficiency are not appropriate candidates for once-daily dosing. CONCLUSION: Once-daily aminoglycoside dosing is an effective, well-established method to achieve therapeutic efficacy while limiting the risk of toxicity and simplifying the processes of dosing and monitoring.
Authors: Tomefa E Asempa; Joseph L Kuti; Julie D Seroogy; Allison S Komirenko; David P Nicolau Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Jacob P Counts; Jessica L Elefritz; Erica E Reed; Marilly Palettas; Connor Aossey; Julia J Beatty Journal: Eur J Drug Metab Pharmacokinet Date: 2022-01-14 Impact factor: 2.441
Authors: Jessica R Tait; Hajira Bilal; Kate E Rogers; Yinzhi Lang; Tae-Hwan Kim; Jieqiang Zhou; Steven C Wallis; Jürgen B Bulitta; Carl M J Kirkpatrick; David L Paterson; Jeffrey Lipman; Phillip J Bergen; Jason A Roberts; Roger L Nation; Cornelia B Landersdorfer Journal: Antibiotics (Basel) Date: 2022-01-13